739 related articles for article (PubMed ID: 10352249)
1. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
2. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
3. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.
Saito K; Sakurai J; Ohata J; Kohsaka T; Hashimoto H; Okumura K; Abe R; Azuma M
J Immunol; 1998 May; 160(9):4225-31. PubMed ID: 9574523
[TBL] [Abstract][Full Text] [Related]
4. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
5. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts.
Mandelbrot DA; Furukawa Y; McAdam AJ; Alexander SI; Libby P; Mitchell RN; Sharpe AH
J Immunol; 1999 Oct; 163(7):3753-7. PubMed ID: 10490971
[TBL] [Abstract][Full Text] [Related]
6. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
[TBL] [Abstract][Full Text] [Related]
7. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E
J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636
[TBL] [Abstract][Full Text] [Related]
8. Costimulation and its role in organ transplantation.
Bluestone JA
Clin Transplant; 1996 Feb; 10(1 Pt 2):104-9. PubMed ID: 8680045
[TBL] [Abstract][Full Text] [Related]
9. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses.
Onodera K; Chandraker A; Schaub M; Stadlbauer TH; Korom S; Peach R; Linsley PS; Sayegh MH; Kupiec-Weglinski JW
J Immunol; 1997 Aug; 159(4):1711-7. PubMed ID: 9257832
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice.
Sabel MS; Hess SD; Egilmez NK; Conway TF; Chen FA; Bankert RB
Cancer Immunol Immunother; 2005 Oct; 54(10):944-52. PubMed ID: 15846492
[TBL] [Abstract][Full Text] [Related]
11. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2.
Webb LM; Walmsley MJ; Feldmann M
Eur J Immunol; 1996 Oct; 26(10):2320-8. PubMed ID: 8898940
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
13. B7-1, but not CD28, is crucial for the maintenance of the CD4+ T cell responses in human leprosy.
Schlienger K; Uyemura K; Jullien D; Sieling PA; Rea TH; Linsley PS; Modlin RL
J Immunol; 1998 Sep; 161(5):2407-13. PubMed ID: 9725237
[TBL] [Abstract][Full Text] [Related]
14. Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft-versus-host disease by an enhanced expansion of regulatory CD8+ T cells.
Sakurai J; Ohata J; Saito K; Miyajima H; Hirano T; Kohsaka T; Enomoto S; Okumura K; Azuma M
J Immunol; 2000 Jan; 164(2):664-9. PubMed ID: 10623808
[TBL] [Abstract][Full Text] [Related]
15. Different costimulation signals used by CD4(+) and CD8(+) cells that independently initiate rejection of allogenic hepatocytes in mice.
Gao D; Li J; Orosz CG; Bumgardner GL
Hepatology; 2000 Nov; 32(5):1018-28. PubMed ID: 11050052
[TBL] [Abstract][Full Text] [Related]
16. CD28-independent costimulation of T cells in alloimmune responses.
Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
[TBL] [Abstract][Full Text] [Related]
17. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM
J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
19. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7.
Damle NK; Klussman K; Leytze G; Myrdal S; Aruffo A; Ledbetter JA; Linsley PS
J Immunol; 1994 Mar; 152(6):2686-97. PubMed ID: 7511623
[TBL] [Abstract][Full Text] [Related]
20. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Vallera DA
Blood; 1995 May; 85(9):2607-18. PubMed ID: 7537122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
